8-KRegulation FD

TransDigm Group INC 8-K Report, Regulation FD Disclosure (Apr 12, 2021)

Filed April 12, 2021For Securities:TDG

Summary

TransDigm Group announced on April 12, 2021, the pricing of a $750 million offering of 4.875% Senior Subordinated Notes due 2029. This offering is being conducted by TransDigm Inc., a wholly-owned subsidiary, and is expected to close on April 21, 2021, subject to customary closing conditions. The company intends to utilize the net proceeds from this new debt issuance, along with existing cash, to redeem its outstanding $750 million aggregate principal amount of 6.500% senior subordinated notes due 2025. This move signifies a proactive refinancing strategy aimed at lowering the company's interest expense and extending its debt maturity profile. The redemption of the 2025 Notes is scheduled for May 15, 2021, with a redemption price of 101.625% of the principal amount, plus accrued interest. The new notes and related guarantees are being offered to qualified institutional buyers and non-U.S. persons under specific exemptions from registration. Investors should note the forward-looking statements contained within the filing, which highlight various risks and uncertainties that could impact TransDigm Group's future financial performance, including factors related to the COVID-19 pandemic, economic conditions, and operational risks.

Key Highlights

  • 1TransDigm Group priced a new $750 million offering of 4.875% Senior Subordinated Notes due 2029.
  • 2The proceeds from the new notes will be used to redeem $750 million of outstanding 6.500% Senior Subordinated Notes due 2025.
  • 3The redemption of the 2025 Notes is set for May 15, 2021, at a premium of 101.625%.
  • 4This refinancing is expected to lower TransDigm's interest expense and extend its debt maturity.
  • 5The offering is being conducted through TransDigm Inc., a wholly-owned subsidiary.
  • 6The new notes and guarantees are being offered to qualified institutional buyers and non-U.S. persons, exempt from registration.
  • 7The filing includes forward-looking statements outlining potential risks affecting future results.

Frequently Asked Questions